Global Viral Respiratory Infections Treatment Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
 Período de pronóstico |
2024 –2031 |
 Tamaño del mercado (año base) |
USD 57,365.34 Million |
 Tamaño del mercado (año de pronóstico) |
USD 108,207.05 Million |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
|
Global Viral Respiratory Infections Treatment Market, By Treatment Type (Antiviral Medications, Vaccine, Monoclonal Antibodies, Non-steroidal Anti-inflammatory Drugs (NSAIDs), and Others), Type (OTC and Prescription Based), Route of Administration (Oral, Nasal, and Injectable), Disease Type (Covid, Influenza (FLU), Respiratory Syncytial Virus (RSV), Parainfluenza, Adenoviruses, Rhinovirus (Common Cold), Enterovirus, Anti-inflammatory, and Others), Infection Type (Upper Respiratory Infections and Lower Respiratory Infections), Population (Pediatric, Adults, and Geriatric), Gender (Male and Female), End User (Hospitals, Home Care Settings, Clinics, Research Institutes and Academic Centers, and Ambulatory Surgical Centers), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2031.
Viral Respiratory Infections Treatment Market Analysis and Size
The increasing prevalence of viral respiratory infections is driving the market growth. However, stringent regulatory approval processes are restraining the market growth. On the other hand, the rising collaborative research activities and partnerships are expected to create opportunities for market growth.
Data Bridge Market Research analyzes that the global viral respiratory infections treatment market is expected to reach USD 108,207.05 million by 2031 from USD 57,365.34 million in 2023, growing at a CAGR of 8.5% in the forecast period of 2024 to 2031.
|
Report Metric |
Details |
|
Forecast Period |
2024 to 2031 |
|
Base Year |
2023 |
|
Historic Year |
2022 (Customizable 2016-2021) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
Treatment Type (Antiviral Medications, Vaccine, Monoclonal Antibodies, Non-steroidal Anti-inflammatory Drugs (NSAIDs), and Others), Type (OTC and Prescription Based), Route of Administration (Oral, Nasal, and Injectable), Disease Type (Covid, Influenza (FLU), Respiratory Syncytial Virus (RSV), Parainfluenza, Adenoviruses, Rhinovirus (Common Cold), Enterovirus, Anti-inflammatory, and Others), Infection Type (Upper Respiratory Infections and Lower Respiratory Infections), Population (Pediatric, Adults, and Geriatric), Gender (Male and Female), End User (Hospitals, Home Care Settings, Clinics, Research Institutes and Academic Centers, and Ambulatory Surgical Centers), Distribution Channel (Direct Tender, Retail Sales, and Others) |
|
Countries Covered |
U.S., Canada, Mexico, Germany, Italy, U.K., France, Switzerland, Spain, Russia, Turkey, Belgium, Netherlands, Rest of Europe, China, India, South Korea, Japan, Thailand, Australia, Singapore, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel and Rest of Middle East and Africa |
|
Market Players Covered |
Pfizer Inc., GSK plc, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson Inc., SINOVAC FAMILY, Lilly, AstraZeneca, Regeneron Pharmaceuticals Inc., Bharat Biotech., Swedish Orphan Biovitrum AB (publ), Serum Institute of India Pvt. Ltd., Biological E Limited, Celltrion Healthcare Co.,Ltd., InflaRx N.V. and among others |
Market Definition
Treatment for viral respiratory infections includes a wide range of medical procedures intended to fight diseases caused by viruses that impact the respiratory system. Many ailments, including the common cold, influenza (flu),Respiratory Syncytial Virus (RSV), adenovirus, and more recently, new viruses such as SARS-CoV-2, which is responsible for COVID-19, are caused by these illnesses, which mostly affect the nose, throat, sinuses, and lungs. A variety of strategies are usually used to treat these illnesses, such as antiviral drugs, supportive care to reduce symptoms, immunization to ward off particular diseases, and, in more serious situations, hospitalization with cutting-edge techniques such as oxygen therapy or mechanical ventilation. The development of novel antiviral medications, vaccinations, and therapeutic approaches to improve treatment efficacy, lessen symptom intensity, and stop the transmission of these extremely contagious respiratory infections is constantly fueled by advances in medical science.
Global Viral Respiratory Infections Treatment Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing Prevalence of Viral Respiratory Infections
The rising incidence of respiratory infections including influenza, Respiratory Syncytial Virus (RSV), and the global impact of the COVID-19 pandemic, has fueled the demand for effective treatment options. The expanding global population, coupled with factors such as urbanization and international travel, has contributed to the rapid spread of respiratory viruses, creating a substantial patient pool in need of therapeutic interventions.
- Government Initiatives and Vaccination Programs
Governments around the world are implementing strategic initiatives to curb the spread of viral respiratory infections by recognizing the significant impact of these diseases on public health. One of the most effective measures has been the promotion and widespread implementation of vaccination programs aimed at preventing key viral respiratory infections such as influenza, pneumonia, and COVID-19. Governments are investing substantial resources to ensure the broad accessibility and affordability of vaccines, contributing to increased vaccination coverage globally.
Opportunity
- Rising Collaborative Research Activities and Partnerships
A multidisciplinary strategy combining partnerships between pharmaceutical companies, academic institutions, governments, and healthcare organizations is necessary due to the complexity of viral respiratory diseases. Collaborative research initiatives that combine resources, information, and skills accelerate the speed of innovation in viral respiratory infection treatments. Collaborations facilitate the exchange of information, scientific discoveries, and innovations in technology, leading to a more thorough comprehension of viruses, their workings, and possible therapeutic approaches. These partnerships provide the way to more effective medication development and discovery procedures. Compared to working alone, researchers can find new therapeutic targets, create innovative antiviral drugs, and develop vaccination technologies more quickly and efficiently when they bring together various perspectives and specialized knowledge.
Restraint/Challenge
- Dependency on Skilled Medical Personnel
The effective diagnosis and treatment of viral respiratory infections often require a high level of expertise and experience among healthcare professionals. The shortage of skilled personnel, particularly in certain regions, causes hindrance to the seamless delivery of healthcare services and limits the market's potential for growth.
The complexity of managing viral respiratory infections, including accurate diagnosis, appropriate treatment selection, and patient care, demands a workforce with specialized skills. The shortage of qualified healthcare professionals, such as infectious disease specialists, pulmonologists, and respiratory therapists, hampers the timely and efficient delivery of healthcare services. This dependency on a skilled workforce creates a bottleneck in regions where there is a scarcity of specialized medical personnel.
Recent Developments
- In August 2023, Regeneron Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority (BARDA) entered into an agreement for a new COVID-19 monoclonal antibody therapy for the prevention of SARS-CoV-2 infection being supported in its clinical development, clinical manufacturing, and regulatory licensure process
- In July 2023, SINOVAC and PT Biofarma announced a major step forward in the two businesses' cooperative efforts to service Indonesia's home vaccination market and the global market
Global Viral Respiratory Infections Treatment Market Scope
The global viral respiratory infections treatment market is segmented into nine notable segments based on treatment type, type, route of administration, disease type, infection type, population, gender, end user, and distribution channel.
Treatment Type
- Antiviral Medications
- Vaccine
- Monoclonal Antibodies
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Others
On the basis of treatment type, the market is segmented into antiviral medications, vaccine, monoclonal antibodies, non-steroidal anti-inflammatory drugs (NSAIDs), and others.
Type
- OTC
- Prescription-Based
On the basis of type, the market is segmented into OTC and prescription-based.
Route of Administration
- Oral
- Nasal
- Injectable
On the basis of route of administration, the market is segmented into oral, nasal, and injectable.
Disease Type
- Covid
- Influenza (FLU)
- Respiratory Syncytial Virus (RSV)
- Parainfluenza
- Adenoviruses
- Rhinovirus (Common Cold)
- Enterovirus
- Others
On the basis of disease type, the market is segmented into covid, influenza (flu), respiratory syncytial virus (RSV), parainfluenza, adenoviruses, rhinovirus (common cold), enterovirus, and others.
Infection Type
- Upper Respiratory Infections
- Lower Respiratory Infections
On the basis of infection type, the market is segmented into upper respiratory infections and lower respiratory infections.
Population
- Pediatric
- Adults
- Geriatric
On the basis of population, the market is segmented into pediatric, adults, and geriatric.
Gender
- Male
- Female
On the basis of gender, the market is segmented into male and female.
End User
- Hospitals
- Home Care Settings
- Clinics
- Research Institutes and Academic Centers
- Ambulatory Surgical Centers
On the basis of end user, the market is segmented into hospitals, home care settings, clinics, research institutes and academic centers, and ambulatory surgical centers.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others.
Global Viral Respiratory Infections Treatment Market Regional Analysis/Insights
The global viral respiratory infections treatment market is segmented into nine notable segments based on treatment type, type, route of administration, disease type, infection type, population, gender, end user, and distribution channel.
The countries covered in this market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Switzerland, Spain, Russia, Turkey, Belgium, Netherlands, Rest of Europe, China, India, South Korea, Japan, Thailand, Australia, Singapore, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel and Rest of Middle East and Africa.
North America is expected to dominate the market due to large investments with rising technological advancements. The U.S. is expected to dominate in the North America region as it possesses a sophisticated healthcare system characterized by advanced medical facilities, cutting-edge research institutions, and a well-established regulatory framework. Germany is expected to dominate in the Europe region due to its exceptional healthcare infrastructure, a concentration of leading pharmaceutical companies, stringent regulatory standards, strategic geographic positioning, and a proactive stance on public health. China is expected to dominate in the Asia-Pacific region as it has a rapidly expanding pharmaceutical sector with a focus on innovation. The presence of both domestic and international pharmaceutical companies has contributed to a dynamic ecosystem that encourages the development of novel antiviral drugs and therapeutics.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Viral Respiratory Infections Treatment Market Share Analysis
The global viral respiratory infections treatment market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the market.
Some of the major market players operating in the global viral respiratory infections treatment market are Pfizer Inc., GSK plc, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson Inc., SINOVAC FAMILY, Lilly, AstraZeneca, Regeneron Pharmaceuticals Inc., Bharat Biotech., Swedish Orphan Biovitrum AB (publ), Serum Institute of India Pvt. Ltd., Biological E Limited, Celltrion Healthcare Co.,Ltd., InflaRx N.V. and among others.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 DBMR MARKET POSITION GRID
2.7 MULTIVARIATE MODELLING
2.8 TYPE LIFELINE CURVE
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 BRAND ANALYSIS
5 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: REGULATIONS
5.1 REGULATIONS IN THE U.S.:
5.2 REGULATIONS IN EUROPE
5.3 REGULATIONS IN INDIA:
5.4 REGULATIONS IN JAPAN
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF VIRAL RESPIRATORY INFECTIONS
6.1.2 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS
6.1.3 ADVANCEMENTS IN MEDICAL RESEARCH AND TECHNOLOGY
6.1.4 GROWING AWARENESS ASSOCIATED WITH RSVS
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATORY APPROVAL PROCESSES
6.2.2 DEPENDENCY ON SKILLED MEDICAL PERSONNEL
6.3 OPPORTUNITIES
6.3.1 RISING COLLABORATIVE RESEARCH ACTIVITIES AND PARTNERSHIPS
6.3.2 ADVANCEMENTS IN ANTIVIRAL DRUG DEVELOPMENT
6.3.3 GROWING FOCUS ON PERSONALIZED TREATMENT OPTIONS
6.4 CHALLENGES
6.4.1 OVERUSE AND MISUSE OF ANTIVIRALS
6.4.2 DIAGNOSTIC ACCURACY AND ACCESSIBILITY
7 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 NON-STEROIDAL ANTI- INFLAMMATORY DRUGS (NSAIDS)
7.2.1 ASPIRIN (ACETYLSALICYLATE)
7.2.2 IBUPROFEN
7.2.3 NAPROXEN
7.2.4 DICLOFENAC
7.2.5 CELECOXIB
7.2.6 OTHERS
7.3 ANTIVIRAL MEDICATIONS
7.3.1 BY TYPE
7.3.1.1 OSELTAMIVIR
7.3.1.2 ZANAMIVIR
7.3.1.3 PERAMIVIR
7.3.1.4 BALOXAVIR MARBOXIL
7.3.1.5 REMEDESVIR
7.3.1.6 NIRMATRELVIR/ RITONAVIR
7.3.1.7 MOLNUPIRAVIR
7.3.1.8 FAVILAVIR
7.3.1.9 OTHERS
7.3.2 BY DRUG TYPE
7.3.2.1 BRANDED
7.3.2.2 GENERIC
7.4 VACCINE
7.4.1 COVID
7.4.1.1 BY TYPE
7.4.1.1.1 WHOLE VIRUS VACCINE
7.4.1.1.1.1 INACTIVATED VACCINE
7.4.1.1.1.2 LIVE ATTENUATED VACCINE
7.4.1.1.2 COMPONENT VIRAL VACCINE
7.4.1.1.2.1 MESSENGER RNA (MRNA) VACCINE
7.4.1.1.2.2 PROTEIN SUBUNIT
7.4.1.1.2.3 VIRUS LIKE PARTICLES (VLP)
7.4.1.2 BY VARIANT
7.4.1.2.1 OMICRON
7.4.1.2.2 ALPHA
7.4.1.2.3 BETA
7.4.1.2.4 DELTA
7.4.1.2.5 OTHERS
7.4.2 INFLUENZA
7.4.2.1 INACTIVATED INFLUENZA VACCINE (IIV)
7.4.2.2 RECOMBINANT INFLUENZA VACCINE (RIV)
7.4.2.3 LIVE ATTENUATED INFLUENZA VACCINE (LAIV)
7.4.3 RESPIRATORY SYNCITIAL VIRUS (RSV)
7.4.4 OTHERS
7.5 MONOCLONAL ANTIBODIES
7.5.1 BY TYPE
7.5.1.1 BARICITINIB
7.5.1.2 REGEN-COV (CASIRIVIMAB AND IMDEVIMAB)
7.5.1.3 TOCILIZUMAB
7.5.1.4 SARILUMAB
7.5.1.5 SOTROVIMAB
7.5.1.6 BAMLANIVIMAB AND ETESEVIMAB
7.5.1.7 CIGLAVIMAB AND TIXAGEVIMAB (EVUSHELD)
7.5.1.8 OTHERS
7.5.2 BY DRUG TYPE
7.5.2.1 BRANDED
7.5.2.2 GENERIC
7.6 OTHERS
8 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 PRESCRIPTION BASED
8.3 OTC
9 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 NASAL
9.3 ORAL
9.3.1 TABLETS
9.3.2 LIQUID
9.3.3 OTHER
9.4 INJECTABLE
9.4.1 INTRAVENOUS
9.4.2 OTHERS
10 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 COVID
10.3 RHINOVIRUS (COMMON COLD)
10.4 RESPIRATORY SYNCYTIAL VIRUS (RSV)
10.5 INFLUENZA (FLU)
10.6 PARAINFLUENZA
10.6.1 HPIV-1
10.6.2 HPIV-2
10.6.3 HPIV-3
10.6.4 HPIV-4
10.7 ADENOVIRUSES
10.8 ENTEROVIRUS
10.8.1 COXSACKIEVIRUS (CV)
10.8.2 POLIOVIRUS (PV)
10.8.3 OTHERS
10.9 OTHERS
11 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE
11.1 OVERVIEW
11.2 LOWER RESPIRATORY INFECTIONS
11.3 UPPER RESPIRATORY INFECTIONS
12 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION
12.1 OVERVIEW
12.2 GERIATRIC
12.3 PEDIATRIC
12.4 ADULTS
13 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER
13.1 OVERVIEW
13.2 MALE
13.3 FEMALE
14 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.2.1 PRIVATE
14.2.2 PUBLIC
14.3 AMBULATORY SURGICAL CENTERS
14.4 CLINICS
14.5 HOME CARE SETTINGS
14.6 RESEARCH INSTITUTES AND ACADEMIC CENTERS
15 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALES
15.3.1 HOSPITAL PHARMACIES
15.3.2 RETAIL PHARMACIES
15.3.3 ONLINE PHARMACIES
15.4 OTHERS
16 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION
16.1 OVERVIEW
16.2 NORTH AMERICA
16.2.1 U.S.
16.2.2 CANADA
16.2.3 MEXICO
16.3 EUROPE
16.3.1 GERMANY
16.3.2 FRANCE
16.3.3 U.K.
16.3.4 ITALY
16.3.5 RUSSIA
16.3.6 SPAIN
16.3.7 TURKEY
16.3.8 NETHERLANDS
16.3.9 SWITZERLAND
16.3.10 BELGIUM
16.3.11 REST OF EUROPE
16.4 ASIA PACIFIC
16.4.1 CHINA
16.4.2 JAPAN
16.4.3 INDIA
16.4.4 SOUTH KOREA
16.4.5 AUSTRALIA
16.4.6 SINGAPORE
16.4.7 THAILAND
16.4.8 MALAYSIA
16.4.9 INDONESIA
16.4.10 PHILIPPINES
16.4.11 REST OF ASIA-PACIFIC
16.5 SOUTH AMERICA
16.5.1 BRAZIL
16.5.2 ARGENTINA
16.5.3 REST OF SOUTH AMERICA
16.6 MIDDLE EAST AND AFRICA
16.6.1 SOUTH AFRICA
16.6.2 SAUDI ARABIA
16.6.3 U.A.E.
16.6.4 EGYPT
16.6.5 ISRAEL
16.6.6 REST OF MIDDLE EAST AND AFRICA
17 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 PFIZER INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 GSK PLC
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 GILEAD SCIENCES, INC
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 F. HOFFMANN-LA ROCHE LTD
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.4.5.1 AGREEMENT
19.5 JOHNSON & JOHNSON SERVICES, INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 ASTRAZENECA
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 BHARAT BIOTECH
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 BIOLOGICAL E LIMITED
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 CELLTRION HEALTHCARE CO., LTD.
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 INFLARX N.V.
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 LILLY
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 REGENERON PHARMACEUTICALS INC.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 SERUM INSTITUTE OF INDIA PVT. LTD
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 SINOVAC
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENT
19.15 SWEDISH ORPHAN BIOVITRUM AB (PUBL)
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tablas
TABLE 1 BRAND REVENUE ANALYSIS FOR VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET
TABLE 2 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 3 GLOBAL NON-STEROIDAL ANTI- INFLAMMATORY DTUGS (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 4 GLOBAL NON-STEROIDAL ANTI- INFLAMMATORY DRUGS(NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 5 GLOBAL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 GLOBAL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 7 GLOBAL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 8 GLOBAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 9 GLOBAL VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 10 GLOBAL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 11 GLOBAL WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 GLOBAL COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 13 GLOBAL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT, 2022-2031 (USD MILLION)
TABLE 14 GLOBAL INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 15 GLOBAL MONOCLONAL ANTIIBODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 GLOBAL MONOCLONAL ANTIBODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 17 GLOBAL MONOCLONAL ANTIBODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 18 GLOBAL OTHERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 19 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 20 GLOBAL PRESCRIPTION BASED IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 21 GLOBAL OTC IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 22 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 23 GLOBAL NASAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 GLOBAL ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 GLOBAL ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 26 GLOBAL INJECTABLE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 27 GLOBAL INJECTABLE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 28 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 29 GLOBAL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 30 GLOBAL RHINOVIRUS (COMMON COLD) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 GLOBAL RESPIRATORY SYNCYTIAL VIRUS (RSV) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 32 GLOBAL INFLUENZA (FLU) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 33 GLOBAL PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 GLOBAL PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 35 GLOBAL ADENOVIRUSES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 36 GLOBAL ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 37 GLOBAL ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 38 GLOBAL OTHERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 39 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 40 GLOBAL LOWER RESPIRATORY INFECTIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 41 GLOBAL UPPER RESPIRATORY INFECTIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 42 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 43 GLOBAL GERIATRIC IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 GLOBAL PEDIATRIC IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 GLOBAL ADULTS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 46 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 47 GLOBAL MALE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 48 GLOBAL FEMALE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 49 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 50 GLOBAL HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 51 GLOBAL HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 GLOBAL AMBULATORY SURGICAL CENTERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 53 GLOBAL CLINICS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 54 GLOBAL HOME CARE SETTINGS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 55 GLOBAL RESEARCH INSTITUTES AND ACADEMIC CENTERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 56 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 57 GLOBAL DIRECT TENDER IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 58 GLOBAL RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 59 GLOBAL RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 60 GLOBAL OTHERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 61 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 62 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 63 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 64 NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 65 NORTH AMERICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 NORTH AMERICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 67 NORTH AMERICA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 68 NORTH AMERICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 69 NORTH AMERICA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 70 NORTH AMERICA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 71 NORTH AMERICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 72 NORTH AMERICA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 73 NORTH AMERICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 NORTH AMERICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 75 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 77 NORTH AMERICA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 78 NORTH AMERICA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 79 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 80 NORTH AMERICA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 81 NORTH AMERICA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 82 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 83 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 84 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 85 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 86 NORTH AMERICA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 87 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 88 NORTH AMERICA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 89 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 90 U.S. NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 91 U.S. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 U.S. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 93 U.S. VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 94 U.S. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 95 U.S. WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 96 U.S. COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 97 U.S. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 98 U.S. INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 99 U.S. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 U.S. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 101 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 102 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 103 U.S. ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 104 U.S. INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 105 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 106 U.S. PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 107 U.S. ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 108 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 109 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 110 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 111 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 112 U.S. HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 113 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 114 U.S. RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 115 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 116 CANADA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 117 CANADA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 118 CANADA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 119 CANADA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 120 CANADA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 121 CANADA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 122 CANADA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 123 CANADA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 124 CANADA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 125 CANADA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 126 CANADA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 127 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 129 CANADA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 130 CANADA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 131 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 132 CANADA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 133 CANADA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 134 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 135 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 136 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 137 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 138 CANADA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 139 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 140 CANADA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 141 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 142 MEXICO NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 143 MEXICO ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 MEXICO ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 145 MEXICO VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 146 MEXICO COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 147 MEXICO WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 148 MEXICO COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 149 MEXICO COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 150 MEXICO INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 151 MEXICO MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 152 MEXICO MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 153 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 154 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 155 MEXICO ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 156 MEXICO INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 157 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 158 MEXICO PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 159 MEXICO ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 160 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 161 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 162 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 163 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 164 MEXICO HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 165 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 166 MEXICO RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 167 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 168 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 169 EUROPE NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 170 EUROPE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 171 EUROPE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 172 EUROPE VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 173 EUROPE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 174 EUROPE WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 175 EUROPE COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 176 EUROPE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 177 EUROPE INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 178 EUROPE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 179 EUROPE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 180 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 182 EUROPE ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 183 EUROPE INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 184 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 185 EUROPE PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 186 EUROPE ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 187 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 188 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 189 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 190 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 191 EUROPE HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 192 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 193 EUROPE RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 194 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 195 GERMANY NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 196 GERMANY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 197 GERMANY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 198 GERMANY VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 199 GERMANY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 200 GERMANY WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 201 GERMANY COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 202 GERMANY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 203 GERMANY INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 204 GERMANY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 205 GERMANY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 206 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 207 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 208 GERMANY ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 209 GERMANY INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 210 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 211 GERMANY PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 212 GERMANY ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 213 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 214 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 215 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 216 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 217 GERMANY HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 218 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 219 GERMANY RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 220 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 221 FRANCE NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 222 FRANCE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 FRANCE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 224 FRANCE VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 225 FRANCE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 226 FRANCE WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 227 FRANCE COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 228 FRANCE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 229 FRANCE INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 230 FRANCE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 231 FRANCE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 232 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 233 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 234 FRANCE ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 235 FRANCE INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 236 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 237 FRANCE PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 238 FRANCE ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 239 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 240 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 241 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 242 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 243 FRANCE HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 244 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 245 FRANCE RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 246 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 247 U.K. NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 U.K. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 249 U.K. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 250 U.K. VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 251 U.K. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 252 U.K. WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 253 U.K. COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 254 U.K. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 255 U.K. INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 256 U.K. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 257 U.K. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 258 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 259 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 260 U.K. ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 261 U.K. INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 262 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 263 U.K. PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 264 U.K. ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 265 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 266 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 267 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 268 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 269 U.K. HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 270 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 271 U.K. RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 272 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 273 ITALY NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 274 ITALY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 275 ITALY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 276 ITALY VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 277 ITALY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 278 ITALY WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 279 ITALY COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 280 ITALY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 281 ITALY INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 282 ITALY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 283 ITALY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 284 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 285 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 286 ITALY ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 287 ITALY INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 288 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 289 ITALY PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 290 ITALY ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 291 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 292 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 293 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 294 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 295 ITALY HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 296 ITALY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 297 ITALY RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 298 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 299 RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 300 RUSSIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 301 RUSSIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 302 RUSSIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 303 RUSSIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 304 RUSSIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 305 RUSSIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 306 RUSSIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 307 RUSSIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 308 RUSSIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 309 RUSSIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 310 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 311 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 312 RUSSIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 313 RUSSIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 314 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 315 RUSSIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 316 RUSSIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 317 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 318 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 319 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 320 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 321 RUSSIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 322 RUSSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 323 RUSSIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 324 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 325 SPAIN NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 326 SPAIN ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 327 SPAIN ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 328 SPAIN VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 329 SPAIN COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 330 SPAIN WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 331 SPAIN COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 332 SPAIN COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 333 SPAIN INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 334 SPAIN MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 335 SPAIN MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 336 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 337 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 338 SPAIN ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 339 SPAIN INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 340 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 341 SPAIN PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 342 SPAIN ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 343 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 344 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 345 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 346 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 347 SPAIN HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 348 SPAIN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 349 SPAIN RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 350 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 351 TURKEY NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 352 TURKEY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 353 TURKEY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 354 TURKEY VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 355 TURKEY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 356 TURKEY WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 357 TURKEY COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 358 TURKEY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 359 TURKEY INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 360 TURKEY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 361 TURKEY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 362 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 363 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 364 TURKEY ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 365 TURKEY INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 366 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 367 TURKEY PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 368 TURKEY ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 369 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 370 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 371 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 372 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 373 TURKEY HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 374 TURKEY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 375 TURKEY RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 376 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 377 NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 378 NETHERLANDS ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 379 NETHERLANDS ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 380 NETHERLANDS VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 381 NETHERLANDS COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 382 NETHERLANDS WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 383 NETHERLANDS COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 384 NETHERLANDS COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 385 NETHERLANDS INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 386 NETHERLANDS MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 387 NETHERLANDS MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 388 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 389 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 390 NETHERLANDS ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 391 NETHERLANDS INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 392 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 393 NETHERLANDS PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 394 NETHERLANDS ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 395 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 396 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 397 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 398 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 399 NETHERLANDS HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 400 NETHERLANDS VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 401 NETHERLANDS RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 402 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 403 SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 404 SWITZERLAND ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 405 SWITZERLAND ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 406 SWITZERLAND VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 407 SWITZERLAND COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 408 SWITZERLAND WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 409 SWITZERLAND COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 410 SWITZERLAND COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 411 SWITZERLAND INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 412 SWITZERLAND MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 413 SWITZERLAND MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 414 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 415 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 416 SWITZERLAND ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 417 SWITZERLAND INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 418 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 419 SWITZERLAND PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 420 SWITZERLAND ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 421 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 422 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 423 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 424 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 425 SWITZERLAND HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 426 SWITZERLAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 427 SWITZERLAND RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 428 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 429 BELGIUM NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 430 BELGIUM ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 431 BELGIUM ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 432 BELGIUM VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 433 BELGIUM COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 434 BELGIUM WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 435 BELGIUM COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 436 BELGIUM COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 437 BELGIUM INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 438 BELGIUM MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 439 BELGIUM MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 440 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 441 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 442 BELGIUM ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 443 BELGIUM INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 444 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 445 BELGIUM PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 446 BELGIUM ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 447 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 448 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 449 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 450 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 451 BELGIUM HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 452 BELGIUM VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 453 BELGIUM RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 454 REST OF EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 455 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 456 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 457 ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 458 ASIA-PACIFIC ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 459 ASIA-PACIFIC ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 460 ASIA-PACIFIC VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 461 ASIA-PACIFIC COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 462 ASIA-PACIFIC WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 463 ASIA-PACIFIC COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 464 ASIA-PACIFIC COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 465 ASIA-PACIFIC INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 466 ASIA-PACIFIC MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 467 ASIA-PACIFIC MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 468 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 469 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 470 ASIA-PACIFIC ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 471 ASIA-PACIFIC INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 472 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 473 ASIA-PACIFIC PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 474 ASIA-PACIFIC ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 475 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 476 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 477 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 478 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 479 ASIA-PACIFIC HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 480 ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 481 ASIA-PACIFIC RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 482 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 483 CHINA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 484 CHINA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 485 CHINA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 486 CHINA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 487 CHINA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 488 CHINA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 489 CHINA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 490 CHINA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 491 CHINA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 492 CHINA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 493 CHINA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 494 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 495 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 496 CHINA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 497 CHINA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 498 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 499 CHINA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 500 CHINA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 501 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 502 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 503 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 504 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 505 CHINA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 506 CHINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 507 CHINA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 508 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 509 JAPAN NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 510 JAPAN ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 511 JAPAN ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 512 JAPAN VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 513 JAPAN COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 514 JAPAN WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 515 JAPAN COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 516 JAPAN COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 517 JAPAN INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 518 JAPAN MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 519 JAPAN MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 520 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 521 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 522 JAPAN ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 523 JAPAN INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 524 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 525 JAPAN PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 526 JAPAN ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 527 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 528 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 529 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 530 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 531 JAPAN HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 532 JAPAN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 533 JAPAN RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 534 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 535 INDIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 536 INDIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 537 INDIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 538 INDIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 539 INDIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 540 INDIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 541 INDIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 542 INDIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 543 INDIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 544 INDIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 545 INDIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 546 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 547 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 548 INDIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 549 INDIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 550 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 551 INDIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 552 INDIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 553 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 554 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 555 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 556 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 557 INDIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 558 INDIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 559 INDIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 560 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 561 SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 562 SOUTH KOREA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 563 SOUTH KOREA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 564 SOUTH KOREA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 565 SOUTH KOREA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 566 SOUTH KOREA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 567 SOUTH KOREA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 568 SOUTH KOREA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 569 SOUTH KOREA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 570 SOUTH KOREA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 571 SOUTH KOREA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 572 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 573 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 574 SOUTH KOREA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 575 SOUTH KOREA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 576 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 577 SOUTH KOREA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 578 SOUTH KOREA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 579 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 580 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 581 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 582 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 583 SOUTH KOREA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 584 SOUTH KOREA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 585 SOUTH KOREA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 586 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 587 AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 588 AUSTRALIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 589 AUSTRALIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 590 AUSTRALIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 591 AUSTRALIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 592 AUSTRALIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 593 AUSTRALIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 594 AUSTRALIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 595 AUSTRALIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 596 AUSTRALIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 597 AUSTRALIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 598 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 599 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 600 AUSTRALIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 601 AUSTRALIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 602 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 603 AUSTRALIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 604 AUSTRALIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 605 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 606 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 607 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 608 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 609 AUSTRALIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 610 AUSTRALIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 611 AUSTRALIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 612 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 613 SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 614 SINGAPORE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 615 SINGAPORE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 616 SINGAPORE VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 617 SINGAPORE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 618 SINGAPORE WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 619 SINGAPORE COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 620 SINGAPORE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 621 SINGAPORE INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 622 SINGAPORE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 623 SINGAPORE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 624 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 625 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 626 SINGAPORE ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 627 SINGAPORE INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 628 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 629 SINGAPORE PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 630 SINGAPORE ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 631 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 632 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 633 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 634 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 635 SINGAPORE HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 636 SINGAPORE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 637 SINGAPORE RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 638 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 639 THAILAND NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 640 THAILAND ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 641 THAILAND ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 642 THAILAND VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 643 THAILAND COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 644 THAILAND WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 645 THAILAND COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 646 THAILAND COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 647 THAILAND INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 648 THAILAND MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 649 THAILAND MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 650 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 651 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 652 THAILAND ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 653 THAILAND INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 654 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 655 THAILAND PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 656 THAILAND ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 657 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 658 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 659 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 660 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 661 THAILAND HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 662 THAILAND VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 663 THAILAND RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 664 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 665 MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 666 MALAYSIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 667 MALAYSIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 668 MALAYSIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 669 MALAYSIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 670 MALAYSIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 671 MALAYSIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 672 MALAYSIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 673 MALAYSIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 674 MALAYSIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 675 MALAYSIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 676 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 677 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 678 MALAYSIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 679 MALAYSIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 680 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 681 MALAYSIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 682 MALAYSIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 683 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 684 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 685 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 686 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 687 MALAYSIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 688 MALAYSIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 689 MALAYSIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 690 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 691 INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 692 INDONESIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 693 INDONESIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 694 INDONESIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 695 INDONESIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 696 INDONESIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 697 INDONESIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 698 INDONESIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 699 INDONESIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 700 INDONESIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 701 INDONESIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 702 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 703 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 704 INDONESIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 705 INDONESIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 706 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 707 INDONESIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 708 INDONESIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 709 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 710 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 711 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 712 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 713 INDONESIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 714 INDONESIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 715 INDONESIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 716 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 717 PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 718 PHILIPPINES ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 719 PHILIPPINES ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 720 PHILIPPINES VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 721 PHILIPPINES COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 722 PHILIPPINES WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 723 PHILIPPINES COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 724 PHILIPPINES COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 725 PHILIPPINES INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 726 PHILIPPINES MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 727 PHILIPPINES MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 728 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 729 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 730 PHILIPPINES ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 731 PHILIPPINES INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 732 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 733 PHILIPPINES PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 734 PHILIPPINES ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 735 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 736 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 737 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 738 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 739 PHILIPPINES HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 740 PHILIPPINES VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 741 PHILIPPINES RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 742 REST OF ASIA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 743 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 744 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 745 SOUTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 746 SOUTH AMERICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 747 SOUTH AMERICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 748 SOUTH AMERICA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 749 SOUTH AMERICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 750 SOUTH AMERICA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 751 SOUTH AMERICA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 752 SOUTH AMERICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 753 SOUTH AMERICA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 754 SOUTH AMERICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 755 SOUTH AMERICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 756 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 757 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 758 SOUTH AMERICA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 759 SOUTH AMERICA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 760 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 761 SOUTH AMERICA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 762 SOUTH AMERICA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 763 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 764 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 765 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 766 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 767 SOUTH AMERICA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 768 SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 769 SOUTH AMERICA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 770 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 771 BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 772 BRAZIL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 773 BRAZIL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 774 BRAZIL VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 775 BRAZIL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 776 BRAZIL WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 777 BRAZIL COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 778 BRAZIL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 779 BRAZIL INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 780 BRAZIL MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 781 BRAZIL MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 782 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 783 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 784 BRAZIL ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 785 BRAZIL INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 786 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 787 BRAZIL PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 788 BRAZIL ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 789 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 790 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 791 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 792 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 793 BRAZIL HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 794 BRAZIL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 795 BRAZIL RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 796 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 797 ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 798 ARGENTINA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 799 ARGENTINA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 800 ARGENTINA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 801 ARGENTINA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 802 ARGENTINA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 803 ARGENTINA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 804 ARGENTINA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 805 ARGENTINA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 806 ARGENTINA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 807 ARGENTINA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 808 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 809 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 810 ARGENTINA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 811 ARGENTINA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 812 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 813 ARGENTINA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 814 ARGENTINA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 815 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 816 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 817 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 818 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 819 ARGENTINA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 820 ARGENTINA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 821 ARGENTINA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 822 REST OF SOUTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 823 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 824 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 825 MIDDLE EAST AND AFRICA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 826 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 827 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 828 MIDDLE EAST AND AFRICA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 829 MIDDLE EAST AND AFRICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 830 MIDDLE EAST AND AFRICA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 831 MIDDLE EAST AND AFRICA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 832 MIDDLE EAST AND AFRICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 833 MIDDLE EAST AND AFRICA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 834 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 835 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 836 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 837 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 838 MIDDLE EAST AND AFRICA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 839 MIDDLE EAST AND AFRICA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 840 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 841 MIDDLE EAST AND AFRICA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 842 MIDDLE EAST AND AFRICA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 843 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 844 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 845 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 846 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 847 MIDDLE EAST AND AFRICA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 848 MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 849 MIDDLE EAST AND AFRICA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 850 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 851 SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 852 SOUTH AFRICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 853 SOUTH AFRICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 854 SOUTH AFRICA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 855 SOUTH AFRICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 856 SOUTH AFRICA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 857 SOUTH AFRICA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 858 SOUTH AFRICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 859 SOUTH AFRICA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 860 SOUTH AFRICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 861 SOUTH AFRICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 862 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 863 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 864 SOUTH AFRICA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 865 SOUTH AFRICA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 866 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 867 SOUTH AFRICA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 868 SOUTH AFRICA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 869 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 870 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 871 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 872 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 873 SOUTH AFRICA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 874 SOUTH AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 875 SOUTH AFRICA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 876 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 877 SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 878 SAUDI ARABIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 879 SAUDI ARABIA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 880 SAUDI ARABIA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 881 SAUDI ARABIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 882 SAUDI ARABIA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 883 SAUDI ARABIA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 884 SAUDI ARABIA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 885 SAUDI ARABIA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 886 SAUDI ARABIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 887 SAUDI ARABIA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 888 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 889 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 890 SAUDI ARABIA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 891 SAUDI ARABIA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 892 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 893 SAUDI ARABIA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 894 SAUDI ARABIA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 895 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 896 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 897 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 898 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 899 SAUDI ARABIA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 900 SAUDI ARABIA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 901 SAUDI ARABIA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 902 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 903 U.A.E. NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 904 U.A.E. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 905 U.A.E. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 906 U.A.E. VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 907 U.A.E. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 908 U.A.E. WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 909 U.A.E. COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 910 U.A.E. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 911 U.A.E. INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 912 U.A.E. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 913 U.A.E. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 914 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 915 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 916 U.A.E. ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 917 U.A.E. INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 918 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 919 U.A.E. PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 920 U.A.E. ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 921 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 922 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 923 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 924 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 925 U.A.E. HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 926 U.A.E. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 927 U.A.E. RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 928 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 929 EGYPT NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 930 EGYPT ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 931 EGYPT ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 932 EGYPT VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 933 EGYPT COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 934 EGYPT WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 935 EGYPT COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 936 EGYPT COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 937 EGYPT INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 938 EGYPT MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 939 EGYPT MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 940 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 941 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 942 EGYPT ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 943 EGYPT INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 944 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 945 EGYPT PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 946 EGYPT ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 947 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 948 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 949 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 950 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 951 EGYPT HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 952 EGYPT VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 953 EGYPT RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 954 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
TABLE 955 ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 956 ISRAEL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 957 ISRAEL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 958 ISRAEL VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION)
TABLE 959 ISRAEL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 960 ISRAEL WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 961 ISRAEL COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 962 ISRAEL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION)
TABLE 963 ISRAEL INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION)
TABLE 964 ISRAEL MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 965 ISRAEL MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 966 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 967 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 968 ISRAEL ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 969 ISRAEL INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 970 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 971 ISRAEL PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 972 ISRAEL ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION)
TABLE 973 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION)
TABLE 974 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 975 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 976 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 977 ISRAEL HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 978 ISRAEL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 979 ISRAEL RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 980 REST OF MIDDLE EAST AND AFRICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION)
Lista de figuras
FIGURE 1 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: SEGMENTATION
FIGURE 2 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: SEGMENTATION
FIGURE 10 NORTH AMERICA REGION IS EXPECTED TO DOMINATE THE GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET AND GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 11 THE INCREASING PREVALENCE OF VIRAL RESPIRATORY DISEASES IS DRIVING THE GROWTH OF THE GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 12 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET IN 2024 AND 2031
FIGURE 13 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET
FIGURE 15 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, 2023
FIGURE 16 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, 2024-2031 (USD MILLION)
FIGURE 17 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2024-2031)
FIGURE 18 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 19 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, 2023
FIGURE 20 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 21 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 22 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 24 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
FIGURE 25 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 26 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 27 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, 2023
FIGURE 28 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, 2024-2031 (USD MILLION)
FIGURE 29 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, CAGR (2024-2031)
FIGURE 30 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 31 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, 2023
FIGURE 32 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, 2024-2031 (USD MILLION)
FIGURE 33 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, CAGR (2024-2031)
FIGURE 34 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, LIFELINE CURVE
FIGURE 35 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, 2023
FIGURE 36 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, 2024-2031 (USD MILLION)
FIGURE 37 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, CAGR (2024-2031)
FIGURE 38 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, LIFELINE CURVE
FIGURE 39 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, 2023
FIGURE 40 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, 2024-2031 (USD MILLION)
FIGURE 41 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 42 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 43 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, 2023
FIGURE 44 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 45 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, CAGR (2024-2031)
FIGURE 46 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 48 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 49 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 50 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: SNAPSHOT (2023)
FIGURE 52 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%)
FIGURE 53 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%)
FIGURE 54 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%)
FIGURE 55 AISA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
